Label-free quantitative proteomics positions the effects and mechanisms of Herba Lysimachiae on synovial diseases based on biolabel-led research pattern.

Some previous studies have demonstrated that Herba Lysimachiae (HL) has a certain protective effect on synovial lesion. But the synovial diseases HL is suitable for treating have remained unclear, as well as the mechanisms involved. To investigate the therapeutic potentials of HL in synovial diseases based on the biolabel-led research pattern. Label-free quantitative proteomics analysis was used to screen the potential biolabels responsible for the intervention of HL on synovium. The effects of HL on the joint swelling and synovial platelet aggregation in osteoarthritis model was applied to confirm the biolabels analysis results. Totally, 140 common proteins were differentially expressed after treatment with HL, out of which 23 were involved in 4 key pathways and considered as the potential biolabels responsible for the interventions of HL on synovium. Biolabels analysis showed that HL increased the levels of the proteins promoting platelet aggregation in physiological situations. The potential biolabels and their related pathways were mainly associated with the pathogenesis of osteoarthritis. In osteoarthritis model, HL inhibited the joint swelling and the overexpression of Itga2b and Itgb3 in synovium to some extent. This study reveals that HL is suitable to treat osteoarthritis. Additionally, HL may produce the dual effects on platelet aggregation in synovium.

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.